atDose Co., Ltd.
Manufacturing of medical devices
License for Manufacturing and Sales of Class I Medical Devices: 14B1X10026
JPY 8.6 million
Asahi-ku, Yokohama, Kanagawa Prefecture
KBIC (Kawasaki Business Incubation Center) #225, 7-7 Shinkawasaki, Saiwai-ku, Kawasaki, Kanagawa Prefecture
Business Development Base
231 Rokugo BASE, 3-10-16 Minami Rokugo, Ota-ku, Tokyo
At atDose, we envision a future where we can thrive alongside our chronic conditions. A future where treating cancer, retinal detachment, and any other diseases, does not limit the quality of time with our loved ones.
We believe that, by providing patient-centric treatment, we can create such a world where patients do not have to give up on their dreams and happiness.
Our core technology, the Electro-Osmotic pump, allows the precise administration of ultra-small doses of medication to specific areas with a strong steady force. It enables the manipulation of high-viscosity medicinal fluids using thin needles, such as 27G. As a result, we anticipate effects such as reducing the side effects of chemotherapy. We aim to realize minimally invasive, patient-centric, and compassionate healthcare.
Manager, Medical Device
Chief of QMS
Audit & Supervisory Board Member
Dr. T. Jeevanandam
Established the Indian subsidiary.
Received the Kanagawa Prefecture Governor’s Award at the “Kanagawa Business Audition 2022.”
Selected for the JETRO “Concentrated Support Program for Overseas Expansion.”
Conducted an additional fundraising of JPY 140 million.
Renewed the logo and website.
Conducted fundraising of JPY 55.5 million.
Launched three products: atDose Core, Mobile, and Multi.
Obtained a license for the manufacture and sale of medical devices.
Featured in the program “Change the World – Building the Future.”
Received the Audience Award at the Yokohama Business Grand Prix.
Selected for the YOXO Accelerator Program.
Commenced collaborative development of equipment for animal experiments with three companies.
Company Award in TECH PLANTER
Selected for the Yokohama Acceleration Program.
Selected for “The Springboard™ Program in Yokohama.”
Selected for KISTEC research projects.
Selected for NEDO NEP.
Established a research institute at KBIC.
Launched atDose in 2017 with a Silicon Valley dispatch.